structur
determin
heteropolytungst
k
h
cl
k
h
pti
w
oh
synthes
evalu
vitro
antivir
activ
hepat
b
hbv
sar
viru
ident
high
puriti
compound
confirm
element
analysi
nmr
ir
analysi
singlecryst
xray
diffract
compound
evalu
hepg
cell
express
perman
hbv
significantli
reduc
level
hbv
antigen
hbv
dna
dosedepend
timedepend
manner
ec
valu
determin
lm
hbeag
lm
hbsag
lm
supernat
hbv
dna
compar
lm
respect
commerciallyavail
hepat
b
drug
adefovir
dipivoxil
adv
intracellular
cccdna
pgrna
hbcag
also
found
decreas
compound
concentrationdepend
manner
cytotox
result
show
compound
low
toxic
hepg
cell
cc
valu
lm
result
indic
compound
effici
inhibit
hbv
replic
hepg
cell
line
vitro
addit
compound
also
show
high
antisar
activ
ec
lm
toxic
cc
lm
mdck
cell
hepat
b
viru
hbv
infect
continu
major
public
health
problem
worldwid
barraud
et
al
million
peopl
worldwid
current
infect
hepat
b
viru
approxim
hbv
patient
develop
chronic
hepat
signific
risk
develop
cirrhosi
liver
hepatocarcinoma
hbv
prototyp
hepadnavirida
famili
small
envelop
hepatotrop
dna
virus
infect
liver
human
marion
robinson
chronic
hepat
b
patient
commonli
treat
either
interferon
alpha
infa
nucleosid
analog
lamivudin
adefovir
entecavir
telbivudin
synthet
revers
transcriptas
inhibitor
de
clercq
delma
et
al
buster
janssen
howev
none
therapi
complet
safe
effect
although
direct
antivir
therapi
amivudin
adefovir
could
effici
control
chronic
activ
hepat
b
drug
resist
renal
toxic
could
develop
progress
sever
month
initi
therapi
thu
still
urgent
requir
identifi
effect
antihbv
agent
polyoxometal
pom
inorgan
clusterlik
complex
constitut
oxid
anion
transit
metal
cation
complex
shown
potenti
applic
multitudin
field
catalysi
medicin
function
materi
especi
medicin
properti
pom
subject
interest
witvrouw
et
al
judd
et
al
shigeta
et
al
yamas
compound
low
toxic
cultur
cell
rel
less
expens
chemic
antivir
drug
recent
pom
report
inhibit
replic
rna
virus
dna
virus
vitro
vivo
human
immunodefici
viru
sever
acut
respiratori
syndrom
sar
viru
influenza
viru
herp
simplex
viru
rhule
et
al
dan
et
al
activ
pom
hepat
b
viru
also
suggest
zoulim
mechan
action
pom
remain
fulli
elucid
may
occur
life
cycl
stage
includ
viral
adsorpt
penetr
reversetranscript
dan
et
al
shigeta
et
al
domail
knoth
ozeki
yamas
show
high
antivir
activ
interest
biolog
result
pw
ti
prompt
us
explor
antivir
activ
compound
contain
pw
ti
anion
potenti
antihbv
agent
also
report
heteropolyoxotungst
pw
ti
broadspectrum
antirna
viru
activ
dan
yamas
therefor
necessari
explor
antivir
activ
compound
contain
pw
ti
sever
acut
respiratori
syndrom
sar
diseas
serious
threaten
human
health
caus
singlestrand
rna
coronaviru
spread
countri
earli
present
worldwid
public
health
concern
drosten
et
al
ksiazek
et
al
research
attent
exploit
antisar
treatment
mainli
focus
vaccin
antivir
drug
integr
tradit
chines
medicin
western
therapi
howev
effect
therapeut
drug
avail
date
stadler
et
al
part
ongo
antivir
drug
discoveri
program
number
pom
analog
synthes
evalu
potenti
antivir
activ
li
et
al
b
result
indic
compound
exhibit
strong
antivir
activ
hbv
sar
virus
low
cytotox
indic
potenti
medicin
candid
hbv
sar
virus
chemic
analyt
grade
use
without
purif
compound
freshli
prepar
character
w
ti
determin
leaman
induct
coupl
plasma
icp
spectromet
infrar
spectrum
record
rang
cm
alpha
centaurt
ftir
spectrophotomet
use
kbr
pellet
w
nmr
spectrum
obtain
bruker
spectromet
oper
mhz
solvent
quantit
rtpcr
perform
abi
sequenc
detect
system
roch
germani
domail
et
al
ad
ml
distil
water
stir
solut
g
mmol
nh
g
mmol
lacl
ad
sequenc
solut
heat
h
water
bath
filter
kept
slow
evapor
undisturb
place
room
temperatur
colorless
crystal
compound
isol
week
yield
base
k
pti
w
measur
compound
collect
rigaku
raxi
rapid
ip
diffractomet
moka
monochrom
radiat
k
k
empir
absorpt
correct
appli
structur
solv
direct
method
refin
fullmatrix
leastsquar
f
use
softwar
sheldrick
nonhydrogen
atom
except
disord
atom
ow
ow
cl
refin
anisotrop
crystallograph
paramet
tabul
tabl
imag
creat
diamond
program
hepg
cell
provid
depart
infecti
diseas
hospit
jilin
univers
pr
china
cultur
dulbecco
modifi
eagl
medium
dmem
gibco
contain
fetal
bovin
serum
fb
gibco
uml
penicillin
uml
streptomycin
lgml
growth
medium
experi
cell
grown
media
describ
without
cell
line
incub
carbon
dioxid
atmospher
prior
exposur
drug
cell
viabil
verifi
accord
standard
trypan
blue
exclus
test
hepg
provid
depart
infecti
diseas
hospit
jilin
univers
pr
china
cultur
dulbecco
modifi
eagl
medium
dmem
gibco
contain
fetal
bovin
serum
fb
gibco
uml
penicillin
uml
streptomycin
cell
line
incub
carbon
dioxid
atmospher
sar
viru
provid
academi
militari
medic
scienc
beij
pr
china
propag
african
green
monkey
kidney
cell
vero
vero
cell
propag
dmem
supplement
fb
mm
lglutamin
uml
penicillin
lgml
streptomycin
bicabou
cell
line
incub
carbon
dioxid
atmospher
drug
steril
filtrat
prior
use
agent
dissolv
dmem
gener
appropri
dose
experiment
nontreat
cell
dmem
alon
use
neg
control
antihbv
activ
compound
cytotox
compound
determin
use
tetrazolium
bromid
tabl
crystal
data
structur
refin
formula
h
clk
pti
w
fw
mtt
assay
previous
describ
kodama
et
al
optic
absorb
read
plate
reader
biorad
co
wavelength
nm
briefli
hepg
cell
plate
plate
densiti
cellsml
h
period
incub
dilut
adv
differ
dose
ad
hepg
cell
neg
control
group
treat
volum
medium
period
incub
mtt
solut
ml
mgml
pb
ad
well
cell
incub
anoth
h
dmso
ml
ad
cytotox
measur
reduct
mtt
observ
mitochondria
h
initi
treatment
cc
defin
concentr
drug
achiev
cytotox
cultur
cell
calcul
bliss
method
han
et
al
supernat
cell
treat
compound
adv
nontreat
cell
collect
semiquantit
detect
hbsag
hbeag
estim
use
elisa
assay
kit
shanghai
kehua
co
ltd
china
supernat
treat
nontreat
cell
collect
hbv
dna
medium
extract
use
hbv
real
quant
pcr
kit
qiagen
kit
china
abi
sequenc
detect
system
appli
biosystem
use
quantifi
purifi
dna
pcr
perform
follow
condit
min
min
follow
amplif
cycl
hepg
cell
harvest
trypsin
digest
wash
three
time
phosphat
buffer
salin
pb
ph
cell
count
use
evalu
presenc
hbv
replic
intermedi
cell
cccdna
cell
pgrna
total
rna
isol
cell
use
trizol
reagent
invitrogen
rtpcr
analysi
rna
reversetranscrib
min
use
commerci
avail
cdna
synthesi
kit
invitrogen
pcr
perform
gene
specif
primer
hbv
bactin
hbv
forward
hbv
revers
bactin
forward
bactin
revers
qpcr
perform
abi
sequenc
detect
system
use
sybr
green
kit
invitrogen
standard
curv
construct
simultan
amplif
serial
dilut
express
plasmid
encod
hbv
target
cdna
normal
endogen
rna
level
bactin
gene
express
determin
use
rel
quantifi
ct
fraction
cycl
number
reach
fix
threshold
ctest
test
hbv
compound
adv
expos
group
ccontrol
refer
control
rna
nontreat
cell
fold
increas
calcul
use
livak
schmittgen
sinc
hbv
cccdna
structur
similar
plasmid
intracellular
cccdna
extract
cell
alkali
lysi
procedur
qiagen
plasmid
mini
kit
ca
order
remov
cellular
chromosom
dna
nonsupercoil
relax
circular
rcdna
purifi
cccdna
dissolv
te
buffer
mm
ph
product
treat
atpdepend
dnase
psad
epicentr
technolog
wi
remov
remain
singlestrand
viru
dna
rcdna
cellular
chromosom
dna
intracellular
cccdna
quantifi
select
fluoresc
pcr
taqman
mgb
probe
capabl
amplifi
check
cccdna
effici
rcdna
hbv
primer
forward
revers
taqman
mg
b
probe
revers
famcctaat
catctc
ttgttcatmgb
qpcr
perform
detect
intracellular
cccdna
use
realquant
pcr
kit
invitrogen
cell
lysat
prepar
use
ripa
radio
immunoprecipit
assay
lysi
buffer
supplement
vv
phenylmethanesulfonylfluorid
pmsf
biyuntian
co
ltd
china
protein
separ
electrophoresi
sodium
dodecyl
sulfatepolyacrylamid
gel
transfer
onto
immobilonp
membran
millipor
analyz
standard
western
blot
techniqu
use
antihbcag
antibodi
santa
cruz
biotechnolog
bactin
santa
cruz
biotechnolog
use
normal
control
antisar
viru
activ
estim
mtt
assay
sigma
optic
absorb
read
plate
reader
biorad
co
wavelength
nm
mtt
vero
cell
cultur
cellsml
prepar
plate
h
period
incub
sar
viru
stock
ml
per
well
differ
dose
compound
ml
per
well
ad
control
group
ml
medium
ad
plate
incub
humidifi
co
atmospher
day
maximum
cytopath
effect
observ
untreat
neg
control
cultur
cytopath
effect
quantit
mtt
assay
briefli
mtt
solut
prepar
dmem
ad
well
plate
incub
h
mtt
solut
remov
without
disturb
cell
dmso
ad
well
dissolv
formazan
crystal
gentli
shake
plate
min
absorb
well
measur
nm
percentag
protect
calcul
b
c
b
b
c
stand
absorb
well
contain
compound
viru
viru
b
cell
c
respect
data
express
mean
sd
standard
deviat
experi
perform
triplic
statist
signific
evalu
oneway
analysi
varianc
anova
student
ttest
multipl
comparison
statist
analyz
use
sa
softwar
version
signific
establish
p
xray
crystallographi
show
compound
consist
polyoxoanion
framework
k
h
pti
w
onedimension
chainlik
k
h
cl
cation
isol
hydroxylamin
nh
oh
compound
polyoxoanion
pti
w
exhibit
wellknown
keggin
structur
fig
central
p
atom
surround
cube
eight
oxygen
atom
oxygen
site
halfoccupi
po
distanc
two
crystallograph
uniqu
surround
metal
site
polyoxoanion
exist
site
occup
disord
center
ti
atom
share
site
occup
respect
form
polyoxoanion
pti
w
fig
asymmetr
unit
compound
center
see
fig
octacoordin
four
l
atom
one
polyoxoanion
two
termin
oxygen
atom
two
polyoxoanion
two
coordin
water
molecul
ko
distanc
rang
thu
center
regard
joint
connect
polyoxoanion
togeth
center
fig
also
exhibit
eight
coordin
environ
two
termin
atom
two
polyoxoanion
four
coordin
water
molecul
two
cl
anion
ko
distanc
rang
kcl
distanc
interest
coordin
atom
share
two
center
base
connect
mode
k
center
form
chain
via
doublebridg
atom
fig
asymmetr
unit
cl
possess
occup
respect
thu
chainlik
cation
describ
k
growth
hepg
cell
presenc
variou
concentr
compound
examin
result
cytotox
experi
given
fig
cytotox
fig
structur
polyoxoanion
compound
show
coordin
site
k
center
coordin
environ
b
center
c
center
level
hbsag
hbeag
extracellular
hbv
dna
medium
measur
differ
time
point
control
group
adv
group
compound
group
respect
shown
fig
treatment
level
hbeag
hbsag
extracellular
hbv
dna
drugtreat
group
decreas
significantli
compar
control
group
concentrationdepend
manner
p
level
hbeag
hbsag
extracellular
hbv
dna
decreas
time
hepg
cell
indic
antihbv
activ
compound
timedepend
p
shown
fig
inhibit
ratio
hbeag
compound
cultur
reach
peak
valu
lm
day
still
kept
day
time
inhibit
ratio
hbsag
shown
fig
reach
peak
valu
lm
day
still
day
inhibit
ratio
hbeag
hbsag
adv
group
lm
respect
inhibitori
valu
hbeag
hbsag
adv
group
decreas
day
interestingli
inhibit
rate
compound
extracellular
hbv
dna
day
day
end
exposur
drug
lower
observ
day
howev
higher
day
time
inhibit
valu
adv
extracellular
hbv
dna
declin
lower
valu
day
shown
fig
result
indic
compound
may
persist
effect
suppress
hbv
effect
concentr
ec
valu
hbeag
hbsag
extracellular
hbv
dna
compound
adv
shown
tabl
therapeut
index
ti
compound
higher
adv
character
antihbv
mechan
compound
amount
intracellular
viral
pgrna
dna
measur
control
group
adv
group
compound
group
differ
concentr
respect
day
shown
fig
result
reveal
level
intracellular
hbv
pgrna
cccdna
decreas
elev
compound
concentr
compar
detect
control
group
p
maximum
inhibit
ratio
pgrna
dna
lm
compound
group
higher
ratio
posit
control
group
avd
group
p
result
suggest
compound
appar
impact
viral
cccdna
replic
viral
pgrna
transcript
hepg
cell
antihbv
mechan
compound
seem
similar
adv
inhibitori
effect
adv
compound
hb
c
ag
protein
level
determin
western
blot
hepg
cell
treat
compound
adv
respect
cell
extract
prepar
analyz
day
shown
fig
level
intracellular
protein
level
hbcag
reduc
elev
compound
concentr
comparison
control
group
p
indic
antihbv
hbcag
activ
compound
concentrationdepend
addit
inhibitori
effect
compound
higher
adv
dose
aim
evalu
antivir
activ
sar
viru
compound
cytotox
compound
vero
cell
first
measur
result
show
maxim
noncytotox
concentr
cc
cytotox
concentr
cc
compound
lm
lm
respect
accord
fig
cytotox
compound
adv
hepg
cell
p
drug
group
vs
control
group
compound
b
p
drug
group
vs
drug
lm
group
c
p
drug
group
vs
drug
lm
group
p
drug
group
vs
drug
lm
group
e
p
vs
drug
lm
group
adv
b
p
drug
group
vs
drug
lm
group
c
p
drug
group
vs
drug
lm
group
p
drug
group
vs
drug
lm
group
e
p
vs
drug
lm
group
cytotox
result
compound
dilut
five
nontox
concentr
lm
antisar
viru
activ
check
mtt
assay
shown
fig
inhibit
ratio
compound
increas
concentr
indic
antisar
viru
activ
compound
concentrationdepend
noteworthi
sar
viru
complet
inhibit
lm
effect
concentr
ec
effect
concentr
ec
lm
respect
ti
compound
current
nucleosid
analog
play
import
role
therapi
hbv
howev
disadvantag
agent
includ
side
effect
drug
resist
cost
limit
clinic
use
hbvinfect
patient
polyoxometal
nonnucleosid
analog
proven
exhibit
broad
inhibitori
activ
human
immunodefici
virus
herp
simplex
viru
influenza
viru
especi
titaniumcontain
polyoxotungst
shown
antivir
activ
varieti
envelop
rna
dna
virus
herein
synthes
titaniumsubstitutedheteropolytungst
k
h
cl
k
h
pti
w
oh
examin
antihbv
activ
vitro
hepg
cell
use
vitro
model
wide
use
evalu
novel
antihbv
drug
chosen
experi
cell
line
contain
multipl
copi
hbv
genom
stabli
integr
host
cell
genom
result
indic
compound
inhibit
hbv
dna
hbsag
hbeag
antigen
cultur
medium
concentrationandtim
depend
manner
lower
concentr
compound
requir
effect
inhibit
secret
hbv
dna
inhibit
secret
antigen
possibl
compound
act
export
virion
outer
protein
coat
although
mechan
mediat
antivir
effect
compound
remain
un
fig
inhibitor
effect
control
group
adv
group
compound
group
secret
hbeag
hbsag
b
extracellular
viral
dna
c
medium
hepg
cell
p
vs
correspond
neg
control
b
p
vs
correspond
day
outcom
dose
c
p
vs
correspond
day
outcom
dose
tabl
antihbv
activ
cytotox
select
index
ti
compound
adv
vitro
hbsag
hbv
dna
clear
deduc
compound
might
block
secret
hbv
contain
nucleocapsid
destabil
hbv
dnacontain
nucleocapsid
interestingli
observ
vitro
antihbv
properti
compound
rebound
serum
hbv
dna
hbsag
hbeag
robust
posit
group
adv
indic
evalu
treat
cell
day
termin
treatment
result
show
compound
sustain
antihbv
activ
level
intracellular
hbv
dna
rna
hbcag
protein
also
reduc
compound
concentrationdepend
manner
adv
drug
competit
inhibit
hbv
polymeras
structur
similar
datp
known
reduc
level
hbv
dna
hbsag
vitro
vivo
phosphoryl
event
facilit
physic
incorpor
nascent
fig
inhibit
effect
level
intracellular
pgrna
cccdna
b
control
group
adv
group
compound
group
differ
concentr
p
vs
correspond
neg
control
b
p
vs
correspond
adv
group
concentr
viral
dna
activ
hbv
polymeras
replic
studi
observ
appar
reduct
level
intracellular
hbvspecif
rna
dna
follow
compound
treatment
data
also
reveal
antihbv
mechan
compound
may
similar
nucleosid
analog
sinc
hbv
pgrna
transcrib
cccdna
presum
hbvspecif
transcript
may
affect
compound
also
import
consid
hbv
pgrna
inhibit
drugtreat
cell
et
al
hbcag
hbsag
hbv
polymeras
translat
pregenom
mrna
minu
strand
hbv
dna
transcrib
pregenom
mrna
templat
studi
found
compound
could
inhibit
level
hbcag
hbsag
hbv
dna
protein
express
concentrationdepend
manner
vitro
result
suggest
compound
appar
interf
viral
pgrna
transcript
hepg
cell
moreov
compound
show
broadspectrum
antivir
activ
effici
inhibit
sar
viru
vero
cell
vitro
low
toxic
mdck
cell
summari
heteropolytungst
prepar
character
vitro
experiment
result
show
compound
potenti
antihbv
antisar
viru
activ
experi
underway
includ
evalu
vivo
activ
determin
mechan
antihbv
activ
compound
